3 completed, 3 recruiting, 1 active not recruiting, 1 enrolling by invitation. 5 Phase 3, 2 Phase 2, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 2, Recruiting 2, Enrolling by invitation 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Focal Seizure: new trials by email Literature Review of Focal Seizure trials Research Report on Focal Seizure
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures RAP-219, Placebo - Focal Seizure, Epilepsy | Phase 3 | Recruiting | Rapport Therapeutics Inc. | 312 | 2026-09-01 | 2026-11-12 |
| Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1 RAP-219, Placebo - Focal Seizure, Epilepsy | Phase 3 | Recruiting | Rapport Therapeutics Inc. | 333 | 2026-06-05 | 2026-11-12 |
| A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures RAP-219 - Focal Epilepsy, Epilepsy | Phase 2 | Recruiting | Rapport Therapeutics Inc. | 30 | 2025-12-15 | 2026-01-23 |
| Clinical Trial of Vormatrigine in Adult Patients With Epilepsy vormatrogine - Epilepsy, Tonic-Clonic, Focal Seizure | Phase 3 | Enrolling by invitation | Praxis Precision Medicines | 700 | 2025-10-27 | 2026-08-03 |
| Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of iQ-007 iQ-007, Placebo - Drug Resistant Epilepsy, Focal Seizure | Phase 1 | Active not recruiting | iQure Australia Pty Ltd | 72 | 2025-04-08 | 2025-12-29 |
| Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1) 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks, Placebo - Focal Seizure | Phase 2 / Phase 3 | Completed | Praxis Precision Medicines | 255 | 2024-12-11 | 2026-08-10 |
| Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy STARSTIM device, Sham Device - Refractory Epilepsy, Focal Seizure | Not applicable | Completed | Neuroelectrics Corporation | 127 | 2021-10-25 | 2026-04-08 |
| Randomized, Double-blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in POS Cenobamate, Placebo - Partial Seizure, Focal Seizure | Phase 3 | Completed | SK Life Science, Inc. | 519 | 2021-03-08 | 2026-06-03 |
Seizures (8) · Epilepsy (5) · Epilepsies, Partial (3) · Drug Resistant Epilepsy (2) · Epilepsy, Tonic-Clonic (2)
Nervous System Diseases (8) · Neurologic Manifestations (8) · Pathological Conditions, Signs and Symptoms (8) · Signs and Symptoms (8) · Brain Diseases (6) · Central Nervous System Diseases (6) · Epilepsy, Generalized (2) · Epilepsy (1)
Cenobamate (1)
Rapport Therapeutics Inc. (3) · Praxis Precision Medicines (2) · Neuroelectrics Corporation (1) · SK Life Science, Inc. (1) · iQure Australia Pty Ltd (1)
United States (6) · Australia (3) · South Korea (3) · Spain (3) · Brazil (2) · Italy (2) · Poland (2) · Belgium (1) · Canada (1) · China (1) · France (1) · Germany (1) · Japan (1) · Mexico (1) · United Kingdom (1)
Henk de Wilde (1) · Imran Quraishi, MD (1) · Vicente Villaneuva, M.D., PhD (1)